| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| General and administrative expenses | $8.8M+86.2% | $4.7M-27.5% | $6.5M+117.2% | $3.0M |
| Research and development expenses | $1.7M-48.0% | $3.3M+110.1% | $1.6M-33.1% | $2.4M |
| Total operating costs | $10.5M+30.9% | $8.0M-6.0% | $8.5M+21.0% | $7.0M |
| Interest income | $99K-40.3% | $166K | — | — |
| Other expense | -$13K | — | — | — |
| Unrealized loss on short-term investment | -$35K | — | — | — |
| Total other income, net | $51K-69.4% | $166K | — | — |
| Net Loss | -$10.4M-33.0% | -$7.9M+34.5% | -$12.0M-69.8% | -$7.1M |
| Deemed dividend | -$21.6M | — | — | — |
| Net loss attributable to common stockholders | -$32.0M-307.5% | -$7.9M+34.5% | -$12.0M-69.8% | -$7.1M |
| Basic loss per share | -$1.35-164.7% | -$0.51+40.0% | -$0.85-112.5% | -$0.40 |
| Diluted loss per share | -$1.35-164.7% | -$0.51+40.0% | -$0.85-112.5% | -$0.40 |
| Basic weighted average common stock shares outstanding | 23.7M+53.4% | 15.4M+10.9% | 13.9M-20.7% | 17.6M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.